Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med Completes Enrollment of Fruquintinib Phase III Trial in CRC

publication date: May 13, 2016
Hutchison China MediTech (Chi-Med) has fully enrolled a China Phase III trial of fruquintinib (HMPL-013) as a treatment for colorectal cancer. The trial enrolled 416 patients with locally advanced or metastatic disease who have previously received two previous rounds of treatment. Fruquintinib, which is also in a Phase III China trial for non-small cell lung cancer, targets VEGFR 1/2/3. Lilly in-licensed rights to the drug in 2013 in a deal worth $86 million plus royalties. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital